NCI-H1299 Xenograft Model Service for NSCLC

The NCI-H1299 xenograft model offers a versatile preclinical platform rooted in a p53-null, KRAS-mutant non-small cell lung cancer background, making it an indispensable tool for evaluating cytotoxic agents, targeted therapies, and metastasis-directed strategies. At Alfa Cytology, we engineer and validate NCI-H1299 xenograft systems with meticulous quality control, delivering reproducible tumor kinetics and multi-layered pharmacodynamic readouts that empower data-driven decision-making throughout your preclinical pipeline.

Overview of NCI-H1299 Xenograft Model for NSCLC

NCI-H1299 is an adherent epithelial cell line originally isolated from a lymph node metastasis of a 43-year-old Caucasian male patient who had received prior radiotherapy. Genetically, this line is distinguished by a homozygous partial deletion of the TP53 locus, resulting in complete absence of p53 protein expression—a feature that renders the cells highly resistant to apoptosis and particularly valuable for studying DNA-damage response pathways and p53-independent cytotoxic mechanisms. The line additionally harbors an activating KRAS mutation and displays elevated epidermal growth factor receptor (EGFR) expression, positioning it within the molecular landscape of aggressive, treatment-refractory NSCLC. In xenograft settings, NCI-H1299 demonstrates reliable engraftment in immunocompromised hosts, with reported tumor take rates ranging from 45% to 100% and palpable masses typically emerging within four to six weeks post-implantation.

Fig 1. Gracillin dose-dependently inhibited NCI-H1299 xenograft growth in nude mice, with 5, 10 and 20 mg/kg reducing final tumor weight by 19.54%, 37.71% and 59.50% respectively, without obvious toxicity. (Xiao, Bang, et al., 2025)

Beyond its utility in conventional subcutaneous drug-efficacy studies, the NCI-H1299 line has been extensively leveraged to model metastatic dissemination through orthotopic, tail-vein, and intra-cardiac delivery routes. These advanced platforms recapitulate organ-specific colonization patterns observed in human disease, including adrenal, osseous, ovarian, and pancreatic metastases. The cell line's pronounced epithelial–mesenchymal transition (EMT) potential—driven by β-catenin, vimentin, and matrix metalloproteinase pathways—further amplifies its relevance for testing anti-metastatic compounds. Collectively, the NCI-H1299 xenograft model serves as a robust, translationally anchored system for interrogating tumor growth, therapeutic resistance, and systemic spread in the NSCLC setting.

Cell Line Information: NCI-H1299

The table below provides a comprehensive reference profile of the NCI-H1299 cell line, consolidating provenance, genetic background, culture requirements, and phenotypic markers essential for experimental planning and quality assurance.

Our Services

Alfa Cytology brings deep proficiency in NSCLC xenograft science to every NCI-H1299 engagement, from cell-line authentication through comprehensive endpoint analysis. Our preclinical team ensures each study is underpinned by validated cell stocks, standardized implantation protocols, and rigorous statistical frameworks—providing you with defensible, reproducible data to advance your therapeutic candidate from lead optimization toward IND-enabling studies.

Workflow of NCI-H1299 Xenograft Model Construction

Building a dependable NCI-H1299 xenograft model requires systematic attention to genetic fidelity, host compatibility, and surgical precision. At Alfa Cytology, we execute a structured, phase-gated workflow that spans from cell-line revival through terminal histopathology, ensuring each model adheres to stringent preclinical benchmarks. Depending on your scientific objectives, we offer subcutaneous models for straightforward efficacy screening, orthotopic pulmonary implants for microenvironment fidelity, or systemic delivery routes (tail-vein or intra-cardiac) for metastasis-focused investigations.

1. Cell Line Authentication and Master Cell Banking NCI-H1299 cells are recovered from cryopreserved master stocks and expanded in RPMI-1640 medium supplemented with 10% FBS. Identity is confirmed by short tandem repeat (STR) profiling against the ATCC reference, and cultures are screened for mycoplasma, bacteria, yeast, and fungal contamination. Only low-passage, log-phase cells are qualified for implantation.
2. Animal Selection and Acclimation Immunodeficient mice—commonly female athymic nude (nu/nu) or NOD-scid gamma (NSG) strains—are procured and quarantined for a minimum of seven days under specific-pathogen-free (SPF) husbandry. Health status is monitored daily, and only animals meeting body-weight and clinical criteria are enrolled.
3. Tumor Cell Preparation and Viability Assessment NCI-H1299 cells are harvested during exponential growth, washed in phosphate-buffered saline, and counted. For subcutaneous implantation, cells are resuspended at 2 × 10⁶ to 1 × 10⁷ per 100–200 µl in serum-free medium mixed with Matrigel (1:1). For metastasis studies, luciferase-expressing NCI-H1299 variants are prepared in PBS alone. Viability is confirmed by trypan blue exclusion (>95% viability required).
4. Xenograft Implantation Subcutaneous models: cell suspension is injected into the flank using a sterile 27-gauge needle. Orthotopic models: cells are delivered into the left lung parenchyma via a thoracotomy or percutaneous intercostal approach under isoflurane anesthesia. Metastasis models: luciferase-labeled cells are administered via tail-vein or intra-cardiac injection to model hematogenous dissemination. Post-procedural analgesia and wound monitoring are provided per IACUC guidelines.
5. Tumor Monitoring and Cohort Randomization Tumor establishment is tracked by caliper measurement (subcutaneous), bioluminescence imaging (metastasis models), or micro-CT (orthotopic). Once tumors reach 100–200 mm³ or bioluminescent signal stabilizes, animals are randomized into treatment and control groups. Body weight and clinical signs are recorded at defined intervals to monitor treatment tolerability.
6. Endpoint Harvest and Multi-Modal Analysis At study termination, tumors and relevant organs are excised, weighed, and photographed. Tissues are fixed in 10% neutral-buffered formalin, paraffin-embedded, and sectioned for hematoxylin and eosin (H&E) staining and immunohistochemistry against Ki-67, cleaved caspase-3, β-catenin, vimentin, and E-cadherin. Supplementary analyses—including western blotting, qPCR, flow cytometry, and TUNEL apoptosis assays—are available upon request.

Fig 2. NCI-H1299 xenograft model construction workflow.

Case Study-NCI-H1299 Xenograft Model Development

In a representative preclinical program, the NCI-H1299 subcutaneous xenograft model was deployed to assess the efficacy of a novel β-catenin pathway inhibitor in suppressing tumor growth and epithelial–mesenchymal transition. Following flank implantation of 5 × 10⁶ NCI-H1299 cells into athymic nude mice, tumors became palpable within 14–18 days and exhibited consistent growth trajectories across the cohort. Animals were randomized once mean tumor volume reached approximately 150 mm³, then assigned to vehicle control or investigational compound arms dosed on a defined schedule. Tumor dimensions were measured biweekly, and tumor growth inhibition was calculated relative to the control group. At endpoint, immunohistochemical analysis of excised tumors revealed dose-dependent reductions in β-catenin and vimentin expression, coupled with restored E-cadherin localization, indicating effective blockade of EMT signaling. Companion tail-vein metastasis studies further demonstrated diminished pulmonary colonization in treated animals, underscoring the translational relevance of the model for anti-metastatic drug evaluation.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology means gaining access to a preclinical infrastructure purpose-built for NSCLC drug development. Our scientific and operational teams integrate deep oncology expertise with rigorous quality systems to generate data you can confidently advance into regulatory discussions and peer-reviewed publications.

• Genetically Verified Cell Stocks – Every NCI-H1299 batch undergoes STR authentication and comprehensive contamination screening before release, safeguarding against genetic drift and experimental artifact.
• Flexible Implantation Strategies – We offer subcutaneous, orthotopic pulmonary, tail-vein, and intra-cardiac delivery routes, allowing you to tailor the tumor microenvironment and metastatic readouts to your compound's mechanism of action.
• p53-Negative Expertise – Our team possesses specialized experience in modeling p53-null tumor biology, enabling nuanced interpretation of DNA-damage response, apoptosis resistance, and synthetic lethality endpoints.
• Integrated EMT and Metastasis Profiling – Beyond standard tumor volume tracking, we provide immunohistochemical and molecular analyses of EMT markers, MMP expression, and metastatic burden to capture the full therapeutic impact of your candidate.
• Regulatory-Grade Data Packages – All studies are conducted under documented protocols with full audit trails, statistical analysis plans, and GLP-aligned documentation suitable for IND submissions and manuscript publication.
• Rapid Study Initiation – With qualified master cell banks and validated surgical procedures in place, we can commence enrollment within days of protocol finalization, compressing your preclinical timeline without compromising quality.

Contact Us

Whether your program targets the p53-null landscape, explores KRAS-directed synthetic lethality, or seeks to disrupt EMT-driven metastasis, Alfa Cytology provides the NCI-H1299 xenograft expertise and infrastructure to propel your NSCLC therapeutic forward. Contact us today to discuss your study parameters, request a customized proposal, or arrange a scientific consultation with our lung cancer modeling specialists. Together, we can transform your therapeutic concept into rigorous, publication-ready preclinical evidence.

For research use only. Not intended for any clinical use.